Novartis: latest news - GoINPHARMA
Monday, 10 December 2018 - 10:44

Novartis

Gilead reports new data on efficacy of CAR-T therapy Yescarta

Gilead has reported results from ZUMA-1 clinical trial, designed to assess the breakthrough investigational therapy Yescarta (axicabtagene ciloleucel), on patients with large B-cell lymphoma. The treatment has been developed by Kite, the biotech acquired by Gilead in 2017. The trial…

Time for radical change at Novartis

Swiss daily newspaper Tagesanzeiger reported that Novartis – with a CHF223bn market capitalization – aims at splitting Sandoz division from the rest of the company, thus making it completely independent. New 42-year-old CEO Vas Narasimhan reportedly said so while dining…

Novartis in constant evolution: new large investment in startup

Israel-based Gamida Cell Ltd is ready for Nasdaq IPO. The young biotech has developed novel, nicotinamide-based cell therapies, the most relevant of which is NiCord, for patients with serious hematologic diseases that need hematopoietic stem cell transplant (HSCT). NiCord is…

M&A splash for Novartis: announced acquisition of Endocyte for $2.1bn

Novartis today announced, before trading opened, that it has acquired the US-based biotech Endocyte for $2.1bn. Novartis has valued the company at $24 per share, that is a 54% premium over yesterday’s closing price. Endocyte is focusing on Precision Medicine,…

How AbbVie protects Humira from biosimilars

Sandoz-Novartis some days ago announced it had reached an agreement with US-based AbbVie. As a result, the launch of Hyrimoz (adalimumab), the biosimilar to blockbuster Humira (adalimumab) was postponed to September 2023. Additionally, the agreement will allow Sandoz to start…

Novartis introduces therapy arsenal for multiple sclerosis

Novartis has introduced today at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Berlin, data related to a clinical trial assessing Gilenya (fingolimod), an oral therapy for MS, in addition…

Vas Narasimhan, Novartis CEO, explains reasons behind 2,100 jobs cut

Novartis new CEO Vas Narasimhan has given a long interview to the Swiss daily Basler Zeitung today. The interview has been almost entirely focused on the cut of approximately 2,100 jobs, announced by the Swiss multinational’s management two days ago….

Novartis announces huge staff cut in Europe

Novartis has announced today the strategic decision that many employees were waiting for and dreading. The Basel-based group has disclosed it plans to cut at least 1,700 jobs in Switzerland and to close down its Grimsby (UK) site, where 395…

New therapies preventing migraine episodes to be launched

US-based drugmaker Eli Lilly & Co. on Friday announced that EMA has recommended the marketing approval in Europe for its monoclonal antibody Emgality (galcanezumab). Emgality has already been granted conditional approval in the US by FDA. It is part of…

Novartis sells US dermatology unit to Aurobindo for 1 billion dollars

Switzerland-based Novartis yesterday evening announced that it has sold its US dermatology unit to Aurobindo Pharma for $900m. The deal includes an additional payment of $100m of potential earn-outs, based on successful completion of precise milestones. The divested unit is…

Everything in place for launch of Novartis’ Kymriah in UK

The UK National Health Service and Novartis yesterday announced they have entered into an agreement to commercialize the immunotherapy Kymriah (tisagenlecleucel) for patients with a rare type of leukemia (ALL) in the UK, but they have not disclosed the price…

Good Phase III results for Novartis’ cancer drug (breast cancer)

Novartis has announced today that its investigational BYL719  (alpelisib) therapy has reached its primary endpoints in the Phase III Solar-1 clinical trial. BYL719 is an alpha-specific PI3K inhibitor developed for the treatment of PIK3CA-mutant breast cancer, tested as intravenous infusion…

Novartis’ pipeline

Paul Hudson, head of Novartis group’s pharmaceutical division, has given a long interview to the weekly Finanz und Wirtschaft today. The main topic has been the controversial issue of  drug prices and, specifically, Trump administration’s request to pharmaceutical companies to…

Novartis pays $1bn for Galapagos’ atopic dermatitis therapy

Novartis has announced it has acquired the rights to an atopic dermatitis treatment from Belgium-based Galapagos and Germany-based MorphoSys. The treatment, named MOR106, is a monoclonal antibody still undergoing clinical trials–a Phase II study was started in May 2018, but…

Moody’s downgrades Novartis’ rating

Last week Novartis announced it was willing to spin off its Alcon unit to create a new independent business worth around $20bn. The idea was positively welcomed by the stock exchange, with shares rising 4%. However, to everyone’s astonishment, credit…

Novartis signed deal with Adamis to gun for Mylan EpiPen’s market

Novartis was granted via subsidiary company Sandoz the U.S. commercial rights for Symjepi, an allergic reaction treatment developed by Adamis Pharmaceuticals. As a matter of fact, Symjepi is a prefilled epinephrine syringe, that is the same active substance as Mylan’s…

NTC acquires part of Novartis’ ophthalmic portfolio

Italy-based pharmaceutical group NTC has acquired part of Novartis’ ophthalmic portfolio for the Spanish, Portuguese, Italian and Polish markets. The acquired products include  Colircusi Gentadexa (aminoglycoside), Colircusi Gentamicin and Oftalmolosa Cusi Gentamicina (aminoglycoside), Oftalmolosa Cusi Erythromycin (macrolide), Oftalmolosa Cusi Aureomycin…

List of likely buyers of Novartis’ Dermatology division ($2bn) takes shape

A list of likely buyers of Novartis’ US dermatology generics division, valued at an approximate $2bn, is now drawn up, Bloomberg has reported. The list includes China-based Shanghai Fosun Pharmaceutical, Apollo Global Management, CVC Capital Partners and India-based Aurobindo Pharma. …

FDA approves Tafinlar + Mekinist combo for thyroid cancer

The FDA has approved the Tafinlar (dabrafenib) + Mekinist (trametinib) combo, by Switzerland-based Novartis, for patients with anaplastic thyroid cancer that cannot be removed by surgery. This is the first therapy approved by FDA for patients with this thyroid cancer…

Aurobindo offers $1.6bn for Sandoz-Novartis’ dermatology (generics) division

India-based Aurobindo Pharma (Hyderabad) has offered $1.6bn for Sandoz’s unit manufacturing and marketing dermatology generics. Other investors are targeting Sandoz’s asset, including pharmaceutical companies and private equities, Livemint has reported. The deadline set by Sandoz to submit offers is June…

Neue Entwicklungen der Membrantechnologie zur Wasserentsalzung

Ein Forscherteam der Zhejiang University von Hangzhou in China hat in der berühmten Zeitschrift Science die Synthese neuer Nanomembranen für die Wasserentsalzung gezeigt. Die neue Membran hat eine Struktur, die eine bessere Separierung großer Ionen ermöglicht und wird durch die…

First quarter meeting expectations for Novartis

Switzerland-based pharmaceutical group Novartis has announced today its Q1 2018 results. These have not satisfied investors, indeed Novartis’ shares have lost almost 3% (Zurich). The group’s profits have increased by 22% ($2.03bn), especially thanks to products against cancer and cardiovascular…

New deal for Novartis

It is widely understood that new Novartis CEO Vas Narasimhan has a far more aggressive managerial style than his predecessor Joseph Jiménez. Since Narasimhan was appointed CEO, Novartis has entered into M&A agreements for a total of $25.8bn: it has…